Beijing Beilu Pharmaceutical Co (SZSE:300016) COGS-to-Revenue : 0.55 (As of Mar. 2025)

View and export this data going back to 2010. Start your Free Trial

What is Beijing Beilu Pharmaceutical Co COGS-to-Revenue?

Beijing Beilu Pharmaceutical Co's Cost of Goods Sold for the three months ended in Mar. 2025 was ¥154 Mil. Its Revenue for the three months ended in Mar. 2025 was ¥283 Mil.

Beijing Beilu Pharmaceutical Co's COGS to Revenue for the three months ended in Mar. 2025 was 0.55.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Beijing Beilu Pharmaceutical Co's Gross Margin % for the three months ended in Mar. 2025 was 45.45%.

Beijing Beilu Pharmaceutical Co COGS-to-Revenue Historical Data

The historical data trend for Beijing Beilu Pharmaceutical Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Beilu Pharmaceutical Co COGS-to-Revenue Chart

Beijing Beilu Pharmaceutical Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.33

0.38

0.45

0.53

0.52

Beijing Beilu Pharmaceutical Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.44	0.53	0.51	0.59	0.55

Beijing Beilu Pharmaceutical Co COGS-to-Revenue Calculation

Beijing Beilu Pharmaceutical Co's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	514.658	/	983.554
	=	0.52

Beijing Beilu Pharmaceutical Co's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	154.192	/	282.681
	=	0.55

Beijing Beilu Pharmaceutical Co (SZSE:300016) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Beijing Beilu Pharmaceutical Co's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	154.192 / 282.681
	=	45.45 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Beijing Beilu Pharmaceutical Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Beijing Beilu Pharmaceutical Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Beilu Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beijing Beilu Pharmaceutical Co Ltd (SZSE:300016) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

N/A

Address

No. 3, Shuiyuan West Road, Miyun District, Beijing, CHN, 100082

Website

http://www.beilu.com.cn

Beijing Beilu Pharmaceutical Co Ltd is engaged in the research and development, production, and sales of pharmaceutical products. The products of the company are contrasted agent series, psychotropic, and hypoglycemic products which include iopamidol injection, iodixanol injection, and reglinide tablets.

Executives

Zong Li	Directors, executives
Hong Cheng Jie	Director
Duan Xian Zhu	Directors, executives
Zhu Zhi	Director
Wang Dai Xue	Director
Li Hong	Directors, executives
Liu Ning	Directors, executives
Wu Rui Hua	Directors, executives
Wu Jie	Executives
Liu Dong Long	Supervisors
Hong Wei	Directors, executives

Beijing Beilu Pharmaceutical Co Headlines

No Headlines